Revenue by Product

(Billions of Yen)

  2014 2015 2016 2017 2018
  Sales 436.9 468.4 472.7 499.3 527.8
  Excl.Tamiflu® 423.8 460.2 459.2 482.4 517.2
  Domestic 349.5 378.0 379.7 388.4 389.2
  Oncology 188.9 215.7 220.3 225.9 225.7
  Avastin® 82.3 93.8 92.1 93.1 95.6
  Herceptin® 31.2 32.7 34.1 33.6 28.1
  Rituxan® 26.2 29.0 32.1 33.4 21.3
  Alecensa® 1.4 8.0 11.9 16.7 20.6
  Perjeta® 9.1 10.6 11.9 13.6 16.1
  Xeloda® 10.4 11.1 12.3 12.2 12.5
  Tarceva® 11.5 11.6 11.5 10.5 8.3
  Kadcyla® 4.0 7.3 8.3 8.0 8.5
  Tecentriq® - - - - 9.1
  Alaglio® - - - 0.0 0.3
  Gazyva® - - - - 0.6
  Zelboraf® - 0.5 0.4 0.1 0.1
  Other products 12.8 11.0 5.8 4.6 4.6
  Bone and joint diseases 69.6 79.4 86.1 93.3 100.5
  Actemra® 24.1 26.8 30.2 33.1 38.2
  Edirol® 19.2 23.1 26.7 29.6 32.9
  Bonviva® 3.4 5.4 7.3 8.7 9.4
  Suvenyl® 10.7 10.5 9.3 8.8 7.8
  Other products 12.3 13.6 12.6 13.1 12.3
  Renal diseases 44.7 45.4 41.1 39.3 36.3
  Mircera® 22.6 23.8 24.2 23.9 23.1
  Oxarol® 12.2 12.9 9.1 8.2 7.3
  Other products 10.0 8.8 7.8 7.2 5.9
  Others 46.4 37.6 32.2 29.9 26.8
  CellCept® 6.5 7.0 7.9 8.9 9.0
  Hemlibra® - - - - 3.0
  Other products 39.8 30.6 24.3 21.0 14.9
  Overseas 74.3 82.2 79.5 94.0 127.9
    Actemra® 55.7 63.6 60.3 60.9 80.6
    To Roche 55.1 62.6 59.1 59.4 78.7
    Alecensa® - 0.5 3.7 13.9 29.5
    To Roche - 0.5 3.7 13.9 28.9
    Neutrogin® 15.7 14.8 12.2 12.3 11.1
    Hemlibra® - - - 3.1 2.3
    Akynzeo® - 0.0 0.1 0.3 0.3
    Aloxi® - 0.3 0.2 0.1 0.1
    Other products 2.9 3.0 3.0 3.5 4.0
  Tamiflu® 13.0 8.2 13.5 16.9 10.7
  Ordinary use 12.9 8.2 12.0 11.9 10.1
  Govt. stockpiles etc. 0.2 0.0 1.5 5.0 0.5
  Royalties and other operating income 24.2 30.4 19.1 34.9 51.9
  Revenues 461.1 498.8 491.8 534.2 579.8
    Domestic 372.9 390.0 395.1 410.9 421.5
    Overseas 88.2 108.8 96.6 123.3 158.3

Sales by Strategic Field (FY2018)

Sales by Strategic Field (FY2018)
  • Amounts are rounded to the nearest 0.1 billion yen.
    Variance and % are calculated based on amounts shown.
    Domestic sales are shown by each disease area.
  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top